This is a cover slide titled "Technical and Commercial Proposal." The subtitle details a "Feasibility Study for Pharmaceutical Manufacturing" involving Nouveta and GTK in Saudi Arabia, with a placeholder for the date.

Technical and Commercial Proposal

Feasibility Study for Pharmaceutical Manufacturing (Nouveta / GTK | Saudi Arabia) [Insert Date]

Source: Centered title & subtitle. Placeholder Nouveta/GTK logos top/bottom. Date: [Insert Date]. Subtle blue-gray background.

This executive summary slide outlines a feasibility study for pharmaceutical manufacturing in Saudi Arabia, evaluating the Nouveta/GTK strategic partnership's viability. It highlights key technical insights, commercial analysis, and coverage of market, regulatory, operational, and financial aspects.

Executive Summary

• Feasibility study for pharmaceutical manufacturing in Saudi Arabia
• Evaluates viability of Nouveta/GTK strategic partnership
• Highlights key technical insights and assessments
• Provides comprehensive commercial viability analysis
• Covers market, regulatory, operational, and financial aspects

The slide titled "Objectives of the Engagement" lists key goals in bullet points. These include analyzing market potential, reviewing regulatory compliance, assessing technical feasibility, developing financial models, and formulating a risk mitigation strategy.

Objectives of the Engagement

• Analyze market potential
• Review regulatory compliance
• Assess technical feasibility
• Develop financial models
• Formulate risk mitigation strategy

Source: Market potential analysis; Regulatory compliance review; Technical feasibility assessment; Financial modeling; Risk mitigation strategy.

The slide outlines four core workstreams—Market, Regulatory/Legal, Technical/Operational, and Financial—using mixed methods like desk research, stakeholder interviews, and modeling. It highlights comprehensive feasibility coverage via an integrated, holistic approach tailored to project objectives and timeline.

Scope of Work and Methodology Overview

• Four core workstreams: Market, Regulatory/Legal, Technical/Operational, Financial
• Mixed methods: Desk research, stakeholder interviews, modeling
• Comprehensive coverage of feasibility dimensions
• Integrated approach for holistic insights
• Tailored to project objectives and timeline

This section header slide introduces "PART A: Technical Proposal" within the "Technical and Commercial Proposal – Feasibility Study for Pharmaceutical Manufacturing (Nouveta / GTK | Saudi Arabia)." The subtitle highlights a comprehensive evaluation of market, regulatory, technical, and financial feasibility dimensions.

Technical and Commercial Proposal – Feasibility Study for Pharmaceutical Manufacturing (Nouveta / GTK | Saudi Arabia)

A

PART A: Technical Proposal

Comprehensive evaluation of market, regulatory, technical, and financial feasibility dimensions.

Source: Nouveta / GTK | Saudi Arabia

The Market Assessment slide's left column outlines its purpose and key activities: conducting demand analysis, comprehensive competitor review, and detailed market forecasts to evaluate market potential. The right column lists outputs: a comprehensive market report summarizing findings and an opportunity matrix highlighting strategic prospects.

Market Assessment

The Regulatory and Legal Assessment slide details a compliance check for Saudi pharmaceutical standards, with key activities including SFDA regulations review, IP assessment, and legal framework evaluation. Key outputs are a detailed risk register of regulatory risks and mitigations, plus a regulatory roadmap with approval timelines and compliance milestones.

Regulatory and Legal Assessment

The Technical and Operational Assessment slide evaluates the viability of a pharmaceutical manufacturing facility through site evaluations, supply chain analysis, and process optimization. Key outputs include a detailed Capex/Opex financial model, technical specifications, equipment lists, and operational blueprints.

Technical and Operational Assessment

Source: PART A: Technical Proposal

The Financial Assessment slide's left column details the purpose of evaluating the pharmaceutical manufacturing project's economic viability through financial projections, sensitivity analyses on costs and volumes, and funding assessments. The right column lists key outputs, including a comprehensive financial model with NPV, IRR, break-even analysis, funding needs, and scenario-based investment recommendations.

Financial Assessment

Source: Technical and Commercial Proposal – Feasibility Study for Pharmaceutical Manufacturing (Nouveta / GTK | Saudi Arabia)

The slide outlines project governance through clear stakeholder roles, weekly steering committee oversight, and proactive risk mitigation. It emphasizes an agile delivery methodology for flexibility, fully aligned with Nouveta and GTK objectives.

Project Governance and Delivery Approach

• Clear roles and responsibilities for all stakeholders
• Weekly steering committee meetings for oversight
• Agile delivery methodology ensuring flexibility
• Proactive risk logs and mitigation strategies
• Full alignment with Nouveta and GTK objectives

The slide outlines a 14-week project timeline across five phases: initiation and market assessment (Weeks 1-2), regulatory/technical assessment (Weeks 3-5), and financial assessment (Weeks 6-8). It concludes with data analysis/synthesis (Weeks 9-12) and reporting/finalization (Weeks 13-14).

Project Timeline (14 Weeks)

Weeks 1-2: Initiation and Market Assessment Project kickoff, team mobilization, and comprehensive market analysis including demand forecasting. Weeks 3-5: Regulatory and Technical Assessment Regulatory compliance review, legal due diligence, and technical/operational feasibility studies. Weeks 6-8: Financial Assessment Financial modeling, cost estimation, and economic viability analysis. Weeks 9-12: Data Analysis and Synthesis Integrate findings from all workstreams and perform in-depth data analysis. Weeks 13-14: Reporting and Finalization Prepare final report, deliverables, and recommendations for decision-making.

Source: Technical and Commercial Proposal – Feasibility Study for Pharmaceutical Manufacturing

The "Key Deliverables" slide lists the project's main outputs in bullet form. These include the Inception Report, four Workstream Reports, Integrated Feasibility Study, Executive Summary, Risk Matrix, and Final Presentation.

Key Deliverables

• Inception Report
• Workstream Reports (4)
• Integrated Feasibility Study
• Executive Summary
• Risk Matrix
• Final Presentation

This slide serves as the section header for Part B: Commercial Proposal, marked as section B. Its subtitle highlights the Commercial Model, Fees, Payment Terms, and Assumptions.

PART B: Commercial Proposal

B

PART B: Commercial Proposal

Commercial Model, Fees, Payment Terms, and Assumptions

The Commercial Model employs a fixed-fee structure for budget predictability, with a total professional fee of [Amount]. This covers the full scope of the feasibility study but excludes travel expenses and add-ons.

Commercial Model

• Fixed-fee model ensures budget predictability
• Total professional fee: [Amount]
• Covers full scope of feasibility study
• Excludes travel expenses and add-ons

Source: Fixed-fee basis for predictability. Total fee: [Amount]. Covers all scope, excludes travel/add-ons.

The "Professional Fees" slide table lists USD fees by workstream: Market (50k), Reg (40k), Tech (60k), Fin (50k), and Governance (20k). The total fees amount to 220k USD.

Professional Fees

{ "headers": [ "Workstream", "Fee (USD)" ], "rows": [ [ "Market", "50k" ], [ "Reg", "40k" ], [ "Tech", "60k" ], [ "Fin", "50k" ], [ "Governance", "20k" ], [ "Total", "220k" ] ] }

The Payment Milestones table lists four stages: Kickoff (20%, 44k), Interim1 (30%, 66k), Interim2 (25%, 55k), and Final (25%, 55k). These payments total 100% or 220k.

Payment Milestones

{ "headers": [ "Milestone", "%", "Amount" ], "rows": [ [ "Kickoff", "20%", "44k" ], [ "Interim1", "30%", "66k" ], [ "Interim2", "25%", "55k" ], [ "Final", "25%", "55k" ] ] }

The slide lists key commercial assumptions: client provides timely access to all necessary data, and the project adheres to a 14-week timeline from kick-off. It also specifies exclusions: all travel, accommodation, and related expenses; optional add-on services (quoted separately); and post-study implementation support.

Commercial Assumptions and Exclusions

• Assumption: Client provides timely access to all necessary data.
• Assumption: Project adheres to 14-week timeline from kick-off.
• Exclusion: All travel, accommodation, and related expenses.
• Exclusion: Optional add-on services (quoted separately).
• Exclusion: Post-study implementation or execution support.

The slide titled "Optional Add-On Services" presents a table listing three services with their fees. These include a Detailed Business Plan for SAR 50k, Site Visits for SAR 30k, and a Funding Pitch Deck for SAR 25k.

Optional Add-On Services

{ "headers": [ "Service", "Fee" ], "rows": [ [ "Detailed Business Plan", "SAR 50k" ], [ "Site Visits", "SAR 30k" ], [ "Funding Pitch Deck", "SAR 25k" ] ] }

The conclusion slide affirms readiness to deliver high-value insights for Nouveta/GTK's success in Saudi pharma. It invites contact to proceed and closes with "Thank you!"

Conclusion

Ready to deliver high-value insights for Nouveta/GTK success in Saudi pharma.

Contact us to proceed.

Thank you!

Source: Technical and Commercial Proposal – Feasibility Study for Pharmaceutical Manufacturing (Nouveta / GTK | Saudi Arabia)